FATI-01 - Trial PACTR201205000384379
Access comprehensive clinical trial information for PACTR201205000384379 through Pure Global AI's free database. This Phase 2 trial is sponsored by French National Agency of Research On Aids and Viral Hepatitis (ANRS); Klinikum der Universität München, Prof. Dr. med. Burkhard Göke and is currently Completed. The study focuses on Infections and Infestations.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Pan Africa Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
French National Agency of Research On Aids and Viral Hepatitis (ANRS); Klinikum der Universität München, Prof. Dr. med. Burkhard Göke
European and Developing Countries Clinical Trials Partnership (EDCTP); German Federal Ministry of Education and Research; French National Agency of Research On Aids and Viral Hepatitis (ANRS); EDCTP
Timeline & Enrollment
Phase 2
Jan 07, 2013
Jan 01, 1900
Summary
A prospective, multicenter, open, randomized Phase 2a trial to confirm a sustained virological suppression defined as HIV-RNA <50 copies/ml of 3 different doses of Fozivudine in context to a standard Zidovudine based antiretroviral therapy regimen after 24 weeks of treatment in ART naïve, non subtype B HIV-1 infected individuals from Tanzania and Ivory Coast.The primary objective is to confirm a sustained virological suppression (HIV RNA <50 copies/ml) after 24 weeks of treatment.
ICD-10 Classifications
Data Source
Pan Africa Clinical Trials Registry
PACTR201205000384379
Non-Device Trial